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Abs t rac t  
Deficiency in N-linked protein glycosylation is a long-known characteristic of alcoholic liver disease and 
congenital disorders of glycosylation. Previous investigations of ethanol-induced glycosylation deficiency 
demonstrated perturbations in the early steps of substrate synthesis and in the final steps of capping N-linked 
glycans in the Golgi. The significance of the biosynthesis of N-glycan precursors in the endoplasmic reticulum, 
however, has not yet been addressed in alcoholic liver disease. Ethanol-metabolizing hepatoma cells were 
treated with increasing concentrations of ethanol. Transcript analysis of genes involved in the biosynthesis of 
N-glycans, activity assays of related enzymes, dolichol-phosphate quantification, and analysis of dolichol-
linked oligosaccharides were performed. Upon treatment of cells with ethanol, we found a decrease in the final 
N-glycan precursor Dol-PP-GlcNAc2Man9Glc3 and in C95- and C100-dolichol-phosphate levels. Transcript 
analysis of genes involved in N-glycosylation showed a 17% decrease in expression levels of DPM1, a subunit 
of the dolichol-phosphate-mannose synthase, and a 8% increase in RPN2, a subunit of the oligosaccharyl 
transferase. Ethanol treatment decreases the biosynthesis of dolichol-phosphate. Consequently, the formation of 
N-glycan precursors is affected, resulting in an aberrant precursor assembly. Messenger RNA levels of genes 
involved in N-glycan biosynthesis are slightly affected by ethanol treatment, indicating that the assembly of N-
glycan precursors is not regulated at the transcriptional level. This study confirms that ethanol impairs N-linked 
glycosylation by affecting dolichol biosynthesis leading to impaired dolichol-linked oligosaccharide assembly. 
Together our data help to explain the underglycosylation phenotype observed in alcoholic liver disease and 
congenital disorders of glycosylation. 
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In t roduc t ion  
Alcoholic liver disease (ALD) displays a broad spectrum of symptoms reflecting the diverse functions of the 
liver. Among the most prominent characteristics of ALD are fatty liver, hepatitis, and liver fibrosis. 
Hepatocytes are responsible for detoxification in the liver and thus for alcohol metabolism. Major metabolic 
changes in hepatocytes occur due to the constant need for ethanol oxidation. Ethanol conversion to acetate leads 
to a shift in the NAD/NADH ratio impairing glycolysis and lipolysis and initiating fatty acid synthesis. The 
inversion of glycolytic flux eventually results in alcoholic fatty liver [Purohit et al., 2009]. Oxidative stress is 
evoked by reactive oxygen species from ethanol breakdown in hepatocytes and toll-like receptor 4 activation by 
LPS leaking from the gut into the blood stream [Wang et al., 2012; Zhu et al., 2012]. This oxidative stress 
contributes to liver inflammation and can lead to liver fibrosis and eventually cirrhosis. Another clinical feature 
in ALD receiving less attention is alcohol-induced deficiency in N-linked protein glycosylation although it has 
been used as a marker for alcohol abuse [Stibler, 1991].  
ALD and congenital disorders of glycosylation (CDG) share some symptoms. Typically, CDG display systemic 
deficiencies like psychomotor retardation with variable neuromuscular involvement and additional features like 
hormonal abnormalities and coagulopathies [Leroy, 2006]. Importantly, fatty liver, hepatitis, and liver fibrosis 
are also found in CDG indicating a possible role of glycosylation in ALD pathology. Indeed, CDG was linked 
to a fibrotic response in fibroblasts involving the insulin-like growth factor-binding protein 5 [Lecca et al., 
2011]. As in CDG, blood serum proteins originating from the liver are not glycosylated properly in ALD. For 
instance, the distribution of carbohydrate-deficient transferrin (CDT) glycoforms found in ALD and CDG are 
similar [Bean and Peter, 1993; de Jong et al., 1992; Petren et al., 1987; Vigo and Adair, 1982]. The two 
glycosylation sites of transferrin are normally occupied with carbohydrates adding up to four branches carrying 
terminal sialic acids. Besides tetrasialo-transferrin, disialo-transferrin is the most prevalent glycoform of 
transferrin in blood serum. In ALD and CDG, asialo- and disialo-transferrin become more apparent and 
tetrasialo-transferrin levels are reduced [Hülsmeier et al., 2007]. In CDG, such a CDT pattern indicates a 
deficiency in the assembly of the N-linked glycan precursor in the ER [Filipovic and Menzel, 1981]. 
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So far, glycosylation deficiency in ALD has been assessed at the levels of Golgi glycosylation and dolichol 
metabolism. However, N-linked glycosylation starts in the ER and requires the synthesis of an oligosaccharide 
precursor on dolichol-phosphate (Dol-P). On the outer leaflet of the ER, one phospho-GlcNAc, one GlcNAc, 
and five Man are sequentially transferred to Dol-P before flipping the resulting Dol-PP-GlcNAc2-Man5 into the 
ER lumen. After the addition of four Man and three Glc residues, the complete N-glycan precursor, Dol-PP-
GlcNAc2-Man9-Glc3 is transferred en bloc to target proteins. Microsomes isolated from rat livers of chronically 
ethanol-fed animals showed a decrease in total dolichol by 36% [Cottalasso et al., 1998; Cottalasso et al., 
1996]. Acute treatment with ethanol of rats resulted in a reduction of total dolichol in liver microsomes by up to 
52%. In a cell culture model, HepG2 cells treated with 50-100 mM ethanol showed decreased transcription of 
the α2,6-sialyltransferase[Garige et al., 2006; Garige et al., 2005; Rao and Lakshman, 1997; Rao and 
Lakshman, 1999]. This enzyme is responsible for terminal sialylation of sugar chains of transferrin in the Golgi 
apparatus. The same effect was observed in the liver from chronically ethanol-fed rats. Additionally, the α2,6-
sialyltransferase mRNA is destabilized by a 3’-untranslated region-specific binding protein. Notably, besides 
downregulation of α2,6-sialyltransferase other effects could cause CDT. Several intermediates along the 
biosynthesis of the N-glycan precursor might be affected, potentially leading to an altered distribution of 
glycoforms. In one study the site occupancy of serum protein glycosylation in an alcohol abusing subject was 
reported to be reduced to levels observed in patients with mild forms of CDG [Hülsmeier et al., 2007]. Another 
study reported the loss of one or both N-glycans as the cause for CDT in patients with severe alcohol abuse 
[Peter et al., 1998]. 
To understand the mechanisms underlying alcohol-induced glycosylation deficiency, we investigated the effects 
of ethanol exposure on the early steps of N-linked protein glycosylation in two cell models. Cultured 
hepatocytes usually lose the expression of drug metabolizing enzymes [Carter and Wands, 1988; Gapp et al., 
2012; Luo et al., 2006; Utesch et al., 1992; Van Kaick et al., 1983]. Therefore, we used two cell lines 
expressing ethanol metabolizing enzymes in our study. First, the HepaRG cell line derived from a human 
hepatocellular carcinoma with an inducible cytochrome p450 system which renders the cell line suitable as a 
model for metabolism of xenobiotics in the human liver [Crick and Carroll, 1987; Eggens et al., 1990; Eggens 
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and Elmberger, 1990; Keller, 1986; Stoll et al., 1988; Yokoyama et al., 1989]. Ethanol degradation via 
cytochrome p450 2E1 (CYP2E1) is a major pathway of ethanol metabolism and can be induced by DMSO 
treatment in HepaRG cells [Koop and Tierney, 1990; Lieber, 1999; Ohnishi and Lieber, 1977]. The second cell 
line, VA-13,  is derived from HepG2 cells, which expresses murine alcohol dehydrogenase 1 (ADH) [Clemens 
et al., 2002]. Ethanol degradation via alcohol dehydrogenase is the second major pathway of ethanol 
metabolism in the liver. We tested the effect of ethanol metabolism in hepatocytes on the N-linked 
glycosylation pathway in the ER and found that N-linked glycosylation is affected at several stages along the 
biosynthetic pathway.
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Mate r ia l s  and  Methods  
Cell lines and experimental conditions 
HepaRG cells were kindly provided by Dr. N. Zitzmann (Department of Biochemistry, University of Oxford, 
UK). HepaRG cells were seeded at a density of 2.6 x 104 cells/cm2 and cultured in Williams’ Medium E 
(Sigma-Aldrich) supplemented with 10% FBS, 5 µg/ml insulin, 2 mM L-glutamine, and 50 µM hydrocortisone 
hemisuccinate for two weeks. To induce maximal induction of the P450 enzymes, HepaRG cells were cultured 
for two additional weeks in the same medium added with 2% DMSO (Sigma) [Gripon et al., 2002]. On day 24 
after seeding, ethanol was added to the medium and culture flasks were sealed with Parafilm to prevent 
evaporation of ethanol. HepaRG cells were harvested and analyzed after 28 days in culture. VA-13 cells were a 
kind gift from Dr. D.L. Clemens (Department of Internal Medicine, University of Nebraska Medical Center, 
USA). VA-13 cells are HepG2 cells stably transfected with an expression plasmid carrying the murine alcohol 
dehydrogenase gene, Adh-1 [Clemens et al., 2002]. VA-13 cells were seeded at a density of 1.7 x 104 cells/cm2 
and ethanol treatment was started 6 h after seeding. VA-13 cells were harvested and analyzed 4 days after 
treatment start. 
Isoelectric focusing gel electrophoresis and immunoblotting 
Supernatant from cultured hepatoma cells was saturated with 0.4 mM ferric citrate in presence of 20 mM 
sodium hydrogen carbonate for 30 min. Samples were analyzed using pre-cast Novex pH 3-7 IEF gels 
(Invitrogen). Gels were run at 7 mA (500 V maximum voltage) for 4 h on ice. Proteins were transferred to a 
nitrocellulose membrane by Western blotting. Transferrin isoforms were visualized using polyclonal rabbit 
anti-human transferrin primary antibody (DakoCytomation, Denmark) and peroxidase-coupled goat anti-rabbit 
secondary antibody (Vector Laboratories, USA). 
Alcohol dehydrogenase activity assay 
Alcohol dehydrogenase (ADH) activity was measured in cell lysates as previously described [Clemens et al., 
1995]. Activity was determined in an assay using ethanol and NAD as substrates. ADH activity was indirectly 
determined from the conversion of NAD by measuring NADH photometrically at 340 nm.  
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Cytochrome P450 2E1 activity assay 
Cytochrome p450 2E1 activity was determined as described previously [Wu and Cederbaum, 2008]. 
Microsomal fractions were prepared and assayed for CYP2E1 activity using p-nitrophenol and NADPH as 
substrates. 
Quantitative PCR for transcript analysis 
Transcript analysis of the glycosylation pathway were quantified with an adapted method for  quantitative PCR 
in mice [Nairn et al., 2010].  Mann-Whitney statistical analysis was done using the InStat software (GraphPad). 
Significance was accepted for p < 0.05. 
Dolichol-phosphate-mannose synthase activity assay 
Cells were grown on 300 cm2 plates and collected by trypsinization. Prior to cell lysis, cells were washed twice 
in ice-cold PBS. The cells were lysed in 25 mM Tris-HCl, 150 mM KCl, 1% Triton X-100, and cell debris was 
removed by centrifugation. Protein concentration was determined by BCA (Pierce). Dolichol-phosphate-
mannose (Dol-P-Man) synthase activity was assayed using 30 ml of cell lysate in 100 ml of reaction buffer, 
with the addition of 40 mg/ml Dol-P (Sigma-Aldrich Co.) and 17 mM GDP-[14C] mannose (Amersham 
Pharmacia Biotech). The reaction buffer contained 50 mM HEPES (pH 7.4), 25 mM KCl, 5 mM MgCl2, 5 mM 
MnCl2, and 0.2% Triton X-100. Reaction mixtures were incubated for 5 min at 37°C. Dol-P-Man was isolated 
by organic extraction with chloroform/methanol (2:1 vol/vol), and radioactivity was determined in a beta 
counter (Beckman Coulter Inc., Fullerton, California, USA) [McLachlan and Krag, 1994]. Statistical 
significance was determined by paired student t-test. Significance was accepted for p < 0.05. 
Fluorescent labeling and analysis of dolichol-phosphate 
Extraction, labeling, and analysis of Dol-P were adapted from previous studies [Elmberger et al., 1989; 
Haeuptle et al., 2010]. Briefly, approximately 3 x 108 cells were collected by trypsinization, counted, and 
washed once in PBS. For quantification, 10 µg C80-polyprenol-phosphate (Larodan Fine Chemicals, Sweden) 
was added as internal standard. After addition of 6 ml methanol and 3 ml 15 M KOH, the sample was 
hydrolyzed for 1 h at 100 °C. Dolichol and Dol-P were extracted with chloroform/methanol (2:1 vol/vol) and 
the chloroform phase was dried under nitrogen. The sample was dissolved in methanol/water (98:2 vol/vol) 
supplemented with 20 mM  phosphoric acid and applied to a C18 SepPak column (Waters, USA). Dolichol and 
Dol-P were eluted in chloroform/methanol (2:1 vol/vol) followed by separation on a Silica SepPak column 
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(Waters, USA). Dol-P was eluted in chloroform/methanol/water (10:10:3 vol/vol/vol). Dol-P was fluorescently 
labeled with 9-anthryldiazomethane (Sigma-Aldrich)  in a multi-step procedure described elsewhere [Haeuptle 
et al., 2010]. 
Samples were analyzed by using a LaChrom D-7000 HPLC system (Merck, Germany) equipped with an 
Inertsil ODS-3 column (5 µm, 4.6 x 250 mm; GL Sciences Inc., Japan). Fluorescence was detected using a 
LaChrom L-7485 fluorescence detector using 365 nm as excitation wavelength and 412 nm as emission 
wavelength. Separation was done by applying isocratic elution with acetonitrile/dichloromethane (3:2 vol/vol) 
supplemented with 0.01% diethylamine (Sigma–Aldrich). Flow was held constant at 1 ml/min at 30 °C. 
Statistical analysis was done by paired student t-test. Significance was accepted for p < 0.05. 
 
Radioactive labeling and analysis of dolichol-linked oligosaccharides 
After ethanol exposure, cells were washed with PBS and incubated in serum- and glucose-free DMEM 
(Invitrogen) for 45 min at 37°C. Metabolic labeling of dolichol-linked oligosaccharide was performed by 
addition of 150 µCi [3H]mannose (Hartmann, Germany) for 1 h at 37°C. Cells were washed twice with PBS and 
scraped in 11 ml methanol and 0.1 mM Tris, pH 7.4 (8:3 vol/vol). After the addition of 12 ml chloroform and 
vortexing, cells were pelleted by centrifugation at 5,000 x g for 5 min. Dolichol-linked oligosaccharides were 
extracted as described previously and were analyzed by HPLC [Burda et al., 1998; Zufferey et al., 1995]. The 
peak areas corresponding to the dolichol-linked oligosaccharides were normalized and the relative signal 
intensities per oligosaccharide were calculated for each run.  Data were subjected to paired t-test for statistical 
analysis. Significance was accepted for p < 0.05. 
 
 Resu l t s  
VA-13 and HepaRG cell lines express ethanol-metabolizing enzymes 
Initially, we assessed the CYP2E1 and ADH activities in the HepaRG and VA-13 cells to confirm their validity 
as ethanol metabolizing cell lines. Expression of murine ADH and induction of CYP2E1 were confirmed in 
VA-13 and HepaRG cells, respectively. ADH activity could not be detected in naïve HepG2 cells but was 
present in VA-13 cells (Figure 1 A). CYP2E1 activity could be induced with 2% DMSO treatment for two 
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weeks in HepaRG cells (Figure 1 B). The activity of ADH and CYP2E1 was reflected in the cytotoxicity 
towards ethanol (Figure 1 C and D). After 4 d of ethanol treatment, viability of VA-13 cells was markedly 
decreased. VA-13 sensitivity towards ethanol has been previously described [Clemens et al., 2002]. Compared 
to rat liver microsomes, the microsomal fractions of induced HepaRG cells showed a 8.6-fold reduced activity 
of CYP2E1. Induced HepaRG cells showed a similar sensitivity to ethanol as the VA-13 cells and viability was 
reduced by 39% upon ethanol treatment. 
Transferrin glycosylation is unaffected by ethanol treatment 
To investigate the production of CDT, hepatocytes were exposed to different concentrations of ethanol for 4 
days and supernatants were analyzed. Supernatants were subjected to isoelectric focusing and immunoblotting 
against transferrin. Transferrin glycoform distribution was different in supernatants of cultured hepatocytes 
compared to blood serum (Figure 2). In contrast to blood serum, supernatants showed more prominent asialo- 
up to trisialo-transferrin bands instead of tetrasialo- and disialo-transferrin, which were prominent in healthy 
control serum. This pattern could be observed both cell lines and reflects the aberrant N-glycosylation found in 
hepatic carcinoma conditions [Kamiyama et al., 2013]. Moreover, no effect on glycoform distribution was 
visible using concentrations between 25 to 200 mM ethanol. A potential effect on the transferrin glycoform 
pattern might be mild and could be masked by the hepatoma specific glycoform distribution. With using higher 
ethanol concentrations, less transferrin was detected. The decrease in transferrin signal reflected low cell 
numbers due to ethanol toxicity or may indicate impaired protein secretion. In contrast, the transferrin signal of 
the parental HepG2 cell line remained stable after exposure to 25 mM or 200 mM ethanol, emphasizing the 
need of ethanol metabolizing enzyme activity to impact protein secretion or protein glycosylation. Hepatoma 
cells and hepatocytes lose their ability to metabolize ethanol due to a significant decline in ADH and CYP2E1 
expression during cell culture. 
Transcript analysis reveals potential regulatory changes along the N-glycosylation 
pathway 
To get more detailed information of changes occurring in the N-linked glycosylation pathway, we analyzed the 
transcripts of different glycosylation genes that are involved in key steps of the Dol-linked oligosaccharide 
assembly by quantitative PCR after 25 mM and 100 mM ethanol treatment for 4 days (Figure 3 A). No 
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significant changes could be observed for the analyzed transcripts upon 25 mM ethanol treatment. After 
treatment with 100 mM ethanol, however, the mRNA levels of two genes were slightly changed. DPM1, a 
subunit of DPM synthase, was downregulated by 17%. DPM synthase works as a heterotrimer (DPM1-DPM3) 
transferring a Man-1-P from GDP-mannose to Dol-P. The resulting Dol-P-Man serves as a substrate for 
mannosyl transferases in the ER lumen. The second transcript RPN2 was upregulated by 8%. RPN2 is a 
ribophorin taking part in the recruitment of the oligosaccharyl transferase complex to the ER-coupled 
ribosomes. We observed a dose dependency on ethanol concentration as a trend in all the tested transcripts. For 
instance, DPM1 mRNA was decreased at 25 mM ethanol but only at 100 mM ethanol the change was 
significant between control and ethanol-treated cells.  
DPM synthase activity was measured to determine whether the lower transcript level of DPM1 would affect 
DPM synthase activity. We found a marked increase in DPM synthase activity in cell lysates from ethanol 
treated VA-13 cells (Figure 3 B). The increase in DPM synthase activity stands in contrast with the minor 
decrease in DPM1 transcript levels. Notably, the catalytic subunit of DPM synthase was not affected at the 
transcriptional level. The moderate downregulation in DPM1 transcript together with the 36% increase in DPM 
synthase activity might point to a regulatory mechanism. 
Dolichol-phosphate pool is decreased after ethanol treatment 
Next, we assessed the most prevalent Dol-P species consisting of 90, 95, and 100 carbon atoms in hepatoma 
cells. Treatment of HepaRG cells with ethanol resulted in a decrease of Dol-P levels (Figure 4). The strongest 
decrease was detected for the C95-Dol-P, which was reduced by 80% whereas C100-Dol-P was decreased by 
64% in comparison to untreated cells (Figure 4 C). 
N-glycan precursor assembly is impaired after ethanol treatment 
In CDG types that affect the biosynthesis of the N-glycan precursor, different intermediate dolichol-linked 
oligosaccharides can accumulate. To address ethanol-induced changes in N-glycan precursor assembly, we 
metabolically labeled dolichol-linked oligosaccharides with [3H]mannose and subsequently separated them by 
HPLC coupled to a flow scintillation analyzer. The dolichol-linked oligosaccharide profile underwent a shift, 
displaying a smaller fraction of the final oligosaccharide precursor when cells were treated with 100 mM 
ethanol (Figure 5 A , B). A reduction of the GlcNAc2-Man9-Glc3 peak by 27% was observed in HepaRG cells 
 11 
 
indicating either a lower availability of dolichol leading to a general decrease is dolichol-linked oligosaccharide 
or a defect in a later stage of the N-glycan biosynthesis in the ER. Typically, defects more early in the 
biosynthesis lead to an accumulation or a uniform decrease of dolichol-linked oligosaccharide precursors 
(Figure 5 C). The same trend of a reduced GlcNAc2-Man9-Glc3 peak could be observed in VA-13 cells (Figure 
5 D). 
 
 D iscuss ion  
We investigated the effect of ethanol exposure on N-linked protein glycosylation and observed lower Dol-P 
levels, in particular C95-Dol-P in our HepaRG model. Lower dolichol levels have been reported previously in 
murine model systems upon ethanol treatment [Cottalasso et al., 1998; Cottalasso et al., 1996]. Dol-P is critical 
for N-glycosylation in two ways. First, it serves as a carrier for the N-glycan precursor. Second, Dol-P coupled 
to Man or Glc is essential for glycosyltransferases located in the ER lumen. Accordingly, low availability of 
Dol-P-Man in DPM1-CDG was previously demonstrated to be attenuated by increasing Dol-P thereby 
compensating the low activity of DPM synthase with better substrate availability [Haeuptle et al., 2011]. The 
strategy of increasing dolichol levels to attenuate glycosylation deficiency in ALD would be interesting but 
might not be sufficient due to the complexity of ethanol-induced N-glycosylation deficiency.  
This is the first study showing ethanol-induced effects on the biosynthesis of the N-glycan precursors, namely a 
reduction of Dol-PP-GlcNAc2Man9Glc3 compared to untreated cells. Interestingly, while general decrease in 
dolichol-linked oligosaccharide is well defined in CDG, such a reduction of the final dolichol-linked precursor 
has not been observed yet, neither in inherited nor in acquired glycosylation deficiencies. The dolichol-linked 
oligosaccharide pattern suggests a deficiency in the ER luminal assembly of the N-glycan precursor or could be 
a consequence of lower dolichol levels. CDG research has shown that deficient enzymes of the early, cytosolic 
steps of N-glycan precursor biosynthesis preferentially lead to an accumulation of Dol-P precursors, such as 
Dol-PP-GlcNAc2-Man5 in DPM1-CDG [Imbach et al., 2000]. The shortage in dolichol could also explain the 
lower Dol-PP-GlcNAc2Man9Glc3 levels with decreased availability of the N-glycan precursors, leading to 
drainage of the dolichol-linked oligosaccharide pool. CDG with deficient dolichol or Dol-P biosynthesis 
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typically result in reduced dolichol-linked oligosaccharide but do not alter the distribution of the dolichol-linked 
precursors as observed in DOLK-CDG [Kranz et al., 2007]. In SRD5A3-CDG, the polyprenol reductase along 
the dolichol biosynthetic pathway is non-functional but does not lead to decreased dolichol levels and 
fibroblasts show a healthy dolichol-linked oligosaccharide distribution [Grundahl et al., 2012]. Symptoms on 
the systemic level are not shared by CDG affecting dolichol biosynthesis and ALD.  The tendency of CDG for 
liver malformation or disease is apparent in other forms of CDG with defects in later steps of the N-linked 
glycosylation pointing towards a more complex mechanism in N-glycosylation deficiency in ALD. 
Transcriptional regulation of N-glycosylation genes could explain ethanol-induced N-glycosylation deficiency. 
We found a trend for transcript alteration upon ethanol treatment but only to a marginal extent. DPM1, a 
subunit of the DPM synthase, was transcriptionally downregulated by 17% indicating a regulatory mechanism. 
This notion is supported by our observation that DPM synthase activity was increased by 36%. More work is 
needed to elucidate possible regulatory mechanisms for the N-glycosylation pathway in ALD. Since reduced 
Dol-PP-GlcNAc2Man9Glc3 might be due to dysfunction of the later, luminal steps of the N-glycan precursor 
assembly, a deregulation of the oligosaccharyl transferase (OST) offers an explanation. Indeed, we found an 
indication for potential OST deregulation. RPN2, a part of the OST complex, was slightly upregulated. RPN2 
was shown to promote glycosylation of P-glycoprotein, an ABC transporter of the multidrug resistance family 
[Honma et al., 2008; Kerb et al., 2001]. Knock-down of RPN2 resulted in reduced glycosylation as well as 
reduced membrane localization of P-glycoprotein. We speculate that RPN2 upregulation upon ethanol-
treatment induces changes in N-linked glycosylation of RPN2 target proteins contributing to an aberrant 
dolichol-linked oligosaccharide pattern. It would be interesting to further investigate the expression and 
function of OST subunits in order to get a notion of the impact of ethanol on OST activity. 
In conclusion, we found that decreased Dol-P and altered dolichol-linked oligosaccharide profiles contribute to 
ethanol-induced N-linked glycosylation deficiency. Furthermore, altered transcription of genes along the N-
linked glycosylation pathway was found indicating a deregulation in N-glycosylation. Together with previous 
findings of lower sialyltransferase and higher sialidase activities, ethanol-induced glycosylation deficiency 
proves to be a result of metabolic interferences along the N-glycosylation biosynthetic pathway starting from 
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the early steps of dolichol synthesis, continuing with the biosynthesis of the N-linked glycan precursor, and 
concluding with the final steps of glycan capping in the Golgi apparatus. 
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Figure legends 
 
Figure 1. Ethanol-metabolizing enzyme activities and viability in VA-13 and HepaRG cell lines. VA-13 
cells were seeded at 16.7 x 103 cells per cm2 and cultured for 4 days previous to ADH activity measurement 
(A). HepaRG cells were treated as described in Materials and Methods and CYP2E1 activity was tested in 
microsomal proteins of induced and un-induced cells (B). Viable cell count was determined after treatment with 
100 mM ethanol for 4 days (C and D). 
Figure 2. Carbohydrate-deficient transferrin as marker for glycosylation deficiency. Transferrin was 
analyzed 4 days after ethanol exposure using isoelectric focusing and subsequent immunoblotting. As a 
comparison, blood serum from a phosphomannomutase 2-CDG patient was analyzed by the same procedure.  
Figure 3. Transcript analysis of the glycosylation pathway in the ER and DPM synthase activity after 100 
mM ethanol treatment. Transcript analysis was performed from RNA of VA-13 cells treated with 25 or 100 
mM ethanol for 4 days (A). Results are shown as mean ± SEM of four independent samples. *, p < 0.05. 
Enzyme activity was determined using cell lysates from treated or untreated VA-13 cells in an assay using C95-
Dol-P as acceptor and radioactive GDP-[3H]mannose as donor substrate (B). The radioactivity of labeled C95-
Dol-P-Man was quantified by liquid scintillation counting. Activities shown as mean ± SEM of six independent 
experiments. *, p < 0.05. 
Figure 4. Dolichol-phosphate levels after 100 mM ethanol treatment. Dol-P levels were determined in 
HepaRG cells after 4 d of ethanol treatment. C90, C95, and C100 peaks were identified using Dol-P standards 
and quantitative determination was done with using C80-Dol-P as internal standard. Representative HPLC 
profiles are shown (A, B). Peak areas were determined and analyzed (C). Data represent mean values ±SEM of 
three independent experiments. *, p < 0.05. 
Figure 5. Dolichol-linked oligosaccharide analysis. VA-13 and HepaRG cells were metabolically labeled 
with [3H]mannose to analyze dolichol-linked oligosaccharide precursors. Representative control and 100 mM 
ethanol treated sample profiles are shown (A and B). Relative peak areas of the GlcNAc2Man9Glc3 to total area 
were calculated (C and D). Data represent mean values ±SEM of three independent experiments. *, p < 0.05. 
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